Equity Market Outlook Q2 2024: Extreme Distortions Everywhere - A Moment For Active Management

Home Market Outlook Today's Equity Market Outlook Q2 2024: Extreme Distortions Everywhere - A Moment For Active Management. Neuberger Berman: U.S. Economic growth has remained resilient and leads the world. Global Industrial Activity Is Picking Up While Early Signs Of Moderating Growth in Europe. We believe extreme market consensus presents a moment for active management.

Weekly Report: what happened at PBE last week (0408-0412)?

Weekly Report: what happened at PBE last week (0401-0405)?

PBE: Biotech Could Be Next Big Winner

Invesco Biotechnology & Genome ETF offers comprehensive exposure to the biotech sector with a diversified portfolio. Biotechnology and genomics sector has not performed well in recent years. PBE has performed better than some similar ETFs but worse than others. The fund is diversified across 32 US biotechnology and genome companies.

Weekly Report: what happened at PBE last week (0325-0329)?

Weekly Report: what happened at PBE last week (0318-0322)?

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

ARK Genomic Revolution ETF warrants a hold rating due to underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. The fund's performance has significantly underperformed the S&P 500 Index. ARKG has a relatively high expense ratio with no dividend yield and is concentrated in the healthcare sector.

Taking Stock: Q2 2024 Equity Market Outlook

Invesco Dynamic Biotechnology & Genome ETF declares quarterly distribution of $0.0242

Invesco Dynamic Biotechnology & Genome ETF (PBE) declares quarterly distribution of $0.0242. Payable Mar 22; for shareholders of record Mar 19; ex-div Mar 18. Invesco Biotechnology and Genome Fund is a passively managed exchange-traded fund.

Weekly Report: what happened at PBE last week (0311-0315)?

2024 Outlook: A New 'Super Boom'? Or Chop And Churn?

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Weekly Report: what happened at PBE last week (0304-0308)?

Why Biotech Stocks May Be Ready For A Recovery

Biotech stocks have struggled in recent quarters as high interest rates take a toll on the capital-intensive sector. Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with MoneyTalk's Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a recovery.

Top 10 best performing biotech stocks of 2024 so far

The biotech sector is +13.6% in 2024. Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors and computer peripherals industries. Top 10 best performing biotech stocks of 2024 so far are Elevation Oncology and Janux.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Weekly Report: what happened at PBE last week (0226-0301)?

Are Healthcare Stocks A Risky Prescription In A U.S. Election Year?

Weekly Report: what happened at PBE last week (0219-0223)?

Weekly Report: what happened at PBE last week (0212-0216)?